Grazirate OD 250 Tablet ER contains divalproex sodium 250 mg, an extended-release formulation designed to provide sustained therapeutic effects. Divalproex is a valproate compound that acts as an anticonvulsant and mood stabilizer, primarily used in the management of epilepsy, bipolar disorder, and migraine prophylaxis. The extended-release formulation allows for once-daily dosing, improving patient compliance by maintaining steady plasma drug concentrations over an extended period. Mechanistically, divalproex increases gamma-aminobutyric acid (GABA) levels in the brain, enhancing inhibitory neurotransmission and stabilizing neuronal activity. This action helps in controlling seizures, stabilizing mood swings, and reducing the frequency of migraine attacks. Grazirate OD 250 is indicated for the treatment of generalized and partial seizures, acute manic episodes associated with bipolar disorder, and prevention of migraine headaches. It is contraindicated in patients with known hypersensitivity to divalproex or valproic acid and those with significant hepatic dysfunction. Common adverse effects include gastrointestinal disturbances, tremor, weight gain, and somnolence. Regular monitoring of liver function tests and blood counts is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Grazirate OD 250 should be used under medical supervision to ensure optimal therapeutic outcomes.